DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Focal segmental Glomerulosclerosis Pipeline, providing valuable insights into emerging therapies, and companies
DelveInsight’s, “Focal Segmental Glomerulosclerosis Pipeline Insight 2023” report provides comprehensive insights about 15+ companies and 18+ pipeline drugs in the Focal Segmental Glomerulosclerosis pipeline landscape. It covers the Focal Segmental Glomerulosclerosis pipeline drug profiles, including Focal Segmental Glomerulosclerosis clinical trials and nonclinical stage products. It also covers the Focal Segmental Glomerulosclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Focal segmental Glomerulosclerosis Pipeline treatment landscape of the report, click here @ Focal segmental Glomerulosclerosis Pipeline Outlook
Key Takeaways from the Focal SegmentalGlomerulosclerosis Pipeline Report
- DelveInsight’s Focal segmental Glomerulosclerosis Pipeline report depicts a robust space with 18+ active players working to develop 18+ pipeline therapies for Focal segmental Glomerulosclerosis.
- The leading Focal segmental Glomerulosclerosis Companies includes Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4, and others
- Promising Focal Segmental Glomerulosclerosis Pipeline Therapies include Acthar Gel, Dapagliflozin, DMX-200, Rituximab, and others
- FSGS with mutations in NPHS2 or TRPC6 is challenging to treat with immunosuppressive therapy; however, when such patients undergo kidney transplantation, the disease does not usually recur. APOL1 G1/G2 variants have been associated with a poor renal prognosis and steroid resistance in nephrotic syndrome/FSGS.
- The Focal segmental Glomerulosclerosis companies and academics are working to assess challenges and seek opportunities that could influence Focal Segmental Glomerulosclerosis R&D. The Focal segmental Glomerulosclerosis therapies under development are focused on novel approaches to treat/improve Focal Segmental Glomerulosclerosis.
For further information, refer to the detailed Focal segmental Glomerulosclerosis Unmet Needs, Focal segmental Glomerulosclerosis Market Drivers, and Focal segmental Glomerulosclerosis Market Barriers, click here for Focal segmental Glomerulosclerosis Ongoing Clinical Trial Analysis
Focal Segmental Glomerulosclerosis Overview
Focal Segmental Glomerulosclerosis (FSGS) is a major cause of idiopathic steroid-resistant nephrotic syndrome (SRNS) and end-stage kidney disease (ESKD). The pathogenesis of focal segmental glomerular sclerosis involves a complex interplay of several cell types, including podocytes, endothelial cells, and the basement membrane. Podocytes are terminally differentiated cells that provide structural support to the glomerulus and are essential in maintaining an intact glomerular filtration barrier, which is essential to prevent nephrotic range proteinuria.
Request a sample and discover the recent advances in Focal segmental Glomerulosclerosis Ongoing Clinical Trial Analysis and Medications, click here @ Focal segmental Glomerulosclerosis Treatment Landscape
Focal Segmental Glomerulosclerosis Emerging Drugs
- DMX-200: Dimerix Bioscience
DMX-200 is a chemokine receptor (CCR2) blocker and is administered to patients taking an angiotensin II type I (AT1) receptor blocker (ARB), which is the standard of care treatment for focal segmental glomerulosclerosis. DMX-200 has been granted patents in various territories until 2032 and has also been granted Orphan Drug Designation by the FDA and EMA. In 2020, DMX-200 demonstrated clear benefit to patients with FSGS in its first Phase IIa study in patients specifically with FSGS, following several successful studies in patients with a range of Chronic Kidney Diseases. All trial endpoints were achieved, and DMX-200 was determined to be safe and tolerable. DMX-200 is currently in a Phase III clinical trial for the treatment of FSGS.
- Sparsentan: Travere Therapeutics
Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate selectively targeting the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease reduces proteinuria, protects podocytes, and prevents glomerulosclerosis and mesangial cell proliferation. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted sparsentan orphan drug designation for FSGS. Currently, Sparsentan is in Phase III development for the treatment of focal segmental glomerulosclerosis (FSGS).
- Dazodalibep: Horizon Therapeutics
Dazodalibep is a CD40 ligand antagonist that blocks T cell interaction with CD40-expressing B cells, disrupting the overactivation of the CD40 ligand co-stimulatory pathway. Several autoimmune diseases are associated with the overactivation of this pathway. Horizon is also investigating dazodalibep in Sjögren’s Syndrome, Rheumatoid Arthritis and Kidney Transplant Rejection. Currently, Dazodalibep is in Phase II development for the treatment of focal segmental glomerulosclerosis (FSGS).
Dive deep into rich insights for drugs for Focal segmental Glomerulosclerosis Market Drivers and Focal segmental Glomerulosclerosis Market Barriers, click here @ Focal segmental Glomerulosclerosis Unmet Needs and Analyst Views
Focal Segmental Glomerulosclerosis Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the therapies for Focal Segmental Glomerulosclerosis. The companies which have their Focal Segmental Glomerulosclerosis drug candidates in the most advanced stage, i.e. phase III include, Dimerix Bioscience.
Scope of the Focal Segmental Glomerulosclerosis Pipeline Report
- Coverage- Global
- Focal Segmental Glomerulosclerosis Companies- Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4, and others
- Focal Segmental Glomerulosclerosis Pipeline Therapies- Acthar Gel, Dapagliflozin, DMX-200, Rituximab, and others
- Focal Segmental Glomerulosclerosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Focal segmental Glomerulosclerosis Mergers and acquisitions, Focal segmental Glomerulosclerosis Licensing Activities @ Focal segmental Glomerulosclerosis Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Executive Summary
- Focal Segmental Glomerulosclerosis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Focal Segmental Glomerulosclerosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- DMX-200: Dimerix Bioscience
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Dazodalibep: Horizon Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Focal Segmental Glomerulosclerosis- Unmet Needs
- Focal Segmental Glomerulosclerosis- Market Drivers and Barriers
- Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services